These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7773 related articles for article (PubMed ID: 2333496)

  • 1. Adoptive immunotherapy for cancer.
    Rosenberg SA
    Sci Am; 1990 May; 262(5):62-9. PubMed ID: 2333496
    [No Abstract]   [Full Text] [Related]  

  • 2. An explanation of the variable clinical response to interleukin 2 and LAK cells.
    Parmiani G
    Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 4. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
    Eggermont AM; Stoter G; Jansen RL; Bolhuis RL
    Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
    Melief CJ
    Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
    [No Abstract]   [Full Text] [Related]  

  • 6. Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
    Strome SE; Krauss JC; Chang AE; Shu S
    J Hematother; 1993; 2(1):63-73. PubMed ID: 7921967
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
    Atzpodien J; Kirchner H
    Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells: acute anergy to mitogens and recall antigens.
    Ades EW; Bosse D; Orr S; Gillespie T
    Pathobiology; 1990; 58(2):78-83. PubMed ID: 2360981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
    Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T
    J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N; Yamasaki S; Harada T; Satoh K; Ichinose Y; Moriguchi Y; Kodama H; Ohgaki K
    Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fighting cancer with designer cells.
    Culliton BJ
    Science; 1989 Jun; 244(4911):1430-3. PubMed ID: 2660264
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 13. [Our experience with lymphocytes activated against cancer: CTL cells].
    Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
    G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adoptive immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes].
    van de Loosdrecht AA; Ossenkoppele GJ; Beelen RH
    Ned Tijdschr Geneeskd; 1989 Oct; 133(40):1994-5. PubMed ID: 2812087
    [No Abstract]   [Full Text] [Related]  

  • 15. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous activated lymphocyte therapy in a community hospital.
    Horváth J; Szabó-Szabari M; Sinkovics JG
    Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2: its rationale and role in the treatment of patients with cancer.
    Rubin JT
    Cancer Treat Res; 1995; 80():83-105. PubMed ID: 8821575
    [No Abstract]   [Full Text] [Related]  

  • 18. [Adoptive immunotherapy with interleukin 2. Initial results of a pilot study in 6 cancer patients].
    Sculier JP; Bron D; Delforge A; Body JJ; Verboven N; Frühling J; Stryckmans P; Klastersky J
    Presse Med; 1989 Jun; 18(23):1155-8. PubMed ID: 2525748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-derived activated cells: culture conditions and characterization.
    Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
    Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
    [No Abstract]   [Full Text] [Related]  

  • 20. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 389.